Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has a price-to-earnings ratio of 25.43x that is above its average ratio. Additionally, the 36-month beta value for CPRX is 0.89. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CPRX is 99.87M and currently, short sellers hold a 5.83% ratio of that float. The average trading volume of CPRX on April 04, 2024 was 1.51M shares.
CPRX) stock’s latest price update
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has seen a rise in its stock price by 1.51 in relation to its previous close of 15.26. However, the company has experienced a -1.65% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-29 that Catalyst (CPRX) reported earnings 30 days ago. What’s next for the stock?
CPRX’s Market Performance
Catalyst Pharmaceuticals Inc (CPRX) has experienced a -1.65% fall in stock performance for the past week, with a -7.19% drop in the past month, and a -9.47% drop in the past quarter. The volatility ratio for the week is 3.58%, and the volatility levels for the past 30 days are at 3.83% for CPRX. The simple moving average for the last 20 days is -4.01% for CPRX stock, with a simple moving average of 10.76% for the last 200 days.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Citigroup repeating the rating for CPRX by listing it as a “Buy.” The predicted price for CPRX in the upcoming period, according to Citigroup is $27 based on the research report published on March 14, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $23. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to CPRX, setting the target price at $30 in the report published on December 21st of the previous year.
CPRX Trading at 3.01% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.98% of loss for the given period.
Volatility was left at 3.83%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares sank -4.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.24% upper at present.
During the last 5 trading sessions, CPRX fell by -1.65%, which changed the moving average for the period of 200-days by +25.22% in comparison to the 20-day moving average, which settled at $16.10. In addition, Catalyst Pharmaceuticals Inc saw -7.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Elsbernd Brian, who sale 25,000 shares at the price of $16.44 back on Mar 27 ’24. After this action, Elsbernd Brian now owns 124,433 shares of Catalyst Pharmaceuticals Inc, valued at $411,000 using the latest closing price.
Harper Molly, the Director of Catalyst Pharmaceuticals Inc, sale 14,000 shares at $14.39 during a trade that took place back on Dec 15 ’23, which means that Harper Molly is holding 0 shares at $201,420 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.85 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.18. The total capital return value is set at 0.22. Equity return is now at value 20.75, with 16.82 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 40.37.
Currently, EBITDA for the company is 119.95 million with net debt to EBITDA at -1.12. When we switch over and look at the enterprise to sales, we see a ratio of 4.25. The receivables turnover for the company is 7.44for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In conclusion, Catalyst Pharmaceuticals Inc (CPRX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
